Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John H Strickler

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
Cancer Discovery|June 3, 2018
<i>EGFR</i> Amplification as a Target in Gastroesophageal Adenocarcinoma: Do Anti-EGFR Therapies Deserve a Second Chance?John H Strickler
Clinical Advances in Hematology & Oncology : H&O|September 22, 2025
The emerging role of antibody-drug conjugates in metastatic colorectal cancerJohn H Strickler
JAMA Oncology|August 16, 2019
The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal CancerKanwal Raghav, John H Strickler
Journal of Gastrointestinal Oncology|October 18, 2016
Clinical applications of liquid biopsies in gastrointestinal oncologyJason Zhu, John H Strickler
The Oncologist|January 12, 2012
Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainabilityJohn H Strickler, Herbert I Hurwitz
The Oncologist|April 6, 2012
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancerJohn H Strickler, Herbert I Hurwitz
Drugs|December 18, 2023
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough TherapiesBennett A Caughey, John H Strickler
Current Oncology Reports|December 3, 2013
Palliative treatment of metastatic colorectal cancer: what is the optimal approach?John H Strickler, Herbert I Hurwitz
Annual Review of Medicine|January 27, 2021
Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal CancerVan K Morris, John H Strickler
Future Oncology (London, England)|November 9, 2023
A study to learn how well tucatinib plus trastuzumab works for treating participants with metastatic colorectal cancer, and how safe it is: a plain language summary of the MOUNTAINEER studyJohn H Strickler, Tanios S Bekaii-Saab
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
Cancer Discovery|June 3, 2018
<i>EGFR</i> Amplification as a Target in Gastroesophageal Adenocarcinoma: Do Anti-EGFR Therapies Deserve a Second Chance?John H Strickler
Clinical Advances in Hematology & Oncology : H&O|September 22, 2025
The emerging role of antibody-drug conjugates in metastatic colorectal cancerJohn H Strickler
JAMA Oncology|August 16, 2019
The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal CancerKanwal Raghav, John H Strickler
Journal of Gastrointestinal Oncology|October 18, 2016
Clinical applications of liquid biopsies in gastrointestinal oncologyJason Zhu, John H Strickler
The Oncologist|January 12, 2012
Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainabilityJohn H Strickler, Herbert I Hurwitz
The Oncologist|April 6, 2012
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancerJohn H Strickler, Herbert I Hurwitz
Drugs|December 18, 2023
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough TherapiesBennett A Caughey, John H Strickler
Current Oncology Reports|December 3, 2013
Palliative treatment of metastatic colorectal cancer: what is the optimal approach?John H Strickler, Herbert I Hurwitz
Annual Review of Medicine|January 27, 2021
Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal CancerVan K Morris, John H Strickler
Future Oncology (London, England)|November 9, 2023
A study to learn how well tucatinib plus trastuzumab works for treating participants with metastatic colorectal cancer, and how safe it is: a plain language summary of the MOUNTAINEER studyJohn H Strickler, Tanios S Bekaii-Saab
Pageof 10